U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852625) titled 'Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients' on Feb. 14.
Brief Summary: The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Kidney Transplant Rejection
Intervention:
BIOLOGICAL: Autologous Tolerogenic Dendritic Cells
* Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a per...